Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 10/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | MPC2 | O95563 | 2/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10638804 | 0.92 | MEN1 (0.44) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL10641964 | 0.92 | CYP3A4 (0.48) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL10640405 | 0.91 | CYP3A4 (0.47) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL8201651 | 0.90 | MAPT (0.52) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL10640410 | 0.90 | CYP3A4 (0.50) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL9631443 | 0.90 | MEN1 (0.50) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL10642092 | 0.90 | CYP3A4 (0.50) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL8975480 | 0.90 | MEN1 (0.50) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL8975476 | 0.90 | MEN1 (0.50) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| SCHEMBL9311289 | 0.89 | MEN1 (0.55) | MEN1MAPTKMT2ATDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999059586-A1 | THIAZOLIDINE AND OXAZOLIDINE DERIVATIVES FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION AND INHIBITION OF CARDIOMYOCYTE APOPTOSIS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-11-25 | — | — | WO | claimed |
| EP-0139421-B1 | THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1988-04-27 | — | — | EP | claimed |
| US-4572912-A | Thiazolidine derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1986-02-25 | — | — | US | claimed |
| EP-0139421-A1 | Thiazolidine derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1985-05-02 | — | — | EP | claimed |
| WO-2011091033-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-5104888-A | Anticholesterol or antidiabetic agents | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0207581-B1 | THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND USE | SANKYO COMPANY LIMITED (JP) | 1990-09-12 | — | — | EP | disclosed |
| EP-0139421-B1 | THIAZOLIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1988-04-27 | — | — | EP | disclosed |
| EP-0207581-A2 | Thiazolidine derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1987-01-07 | — | — | EP | disclosed |
| US-4572912-A | Thiazolidine derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1986-02-25 | — | — | US | disclosed |
| EP-0139421-A1 | Thiazolidine derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | MEN1 4688/4885MAPT 1770/4885KMT2A 2542/4885 |
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | MEN1 836/4885MAPT 1774/4885KMT2A 2465/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | MEN1 914/4885MAPT 4166/4885KMT2A 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.